• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$119.99
+0 (0.00%)
Get New Heska Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSKA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSKA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Heska in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $119.99.

This chart shows the closing price for HSKA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Heska. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2023Morgan StanleyBoost TargetEqual Weight$58.00 ➝ $120.00Low
4/3/2023Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
4/3/2023Alliance Global PartnersDowngradeBuy ➝ NeutralLow
3/2/2023Piper SandlerLower Target$165.00 ➝ $150.00Low
3/1/2023Alliance Global PartnersBoost Target$119.00 ➝ $129.00Low
1/6/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$58.00Low
11/14/2022Piper SandlerLower TargetOverweight$170.00 ➝ $165.00Low
11/9/2022Morgan StanleyLower TargetEqual Weight$149.00 ➝ $135.00Low
11/9/2022Alliance Global PartnersLower TargetBuy$155.00 ➝ $119.00Low
10/17/2022JPMorgan Chase & Co.Lower TargetOverweight$175.00 ➝ $150.00Low
8/22/2022Piper SandlerBoost Target$170.00Low
8/16/2022Piper SandlerBoost TargetOverweight$165.00 ➝ $170.00Low
5/19/2022Alliance Global PartnersBoost Target$150.00 ➝ $155.00Low
5/15/2022Piper SandlerLower TargetNA$190.00 ➝ $180.00High
5/10/2022Alliance Global PartnersLower Target$240.00 ➝ $150.00High
3/17/2022Piper SandlerLower TargetOverweight$210.00 ➝ $190.00High
3/2/2022Alliance Global PartnersLower Target$310.00 ➝ $240.00Low
3/1/2022Morgan StanleyLower TargetEqual Weight$190.00 ➝ $161.00Low
2/23/2022JPMorgan Chase & Co.Lower TargetOverweight$300.00 ➝ $250.00High
11/18/2021Morgan StanleyInitiated CoverageEqual Weight$190.00Medium
8/4/2021Alliance Global PartnersReiterated RatingBuy$240.00 ➝ $310.00Low
8/4/2021Piper SandlerBoost TargetOverweight$240.00 ➝ $305.00Medium
7/12/2021GuggenheimUpgradeNeutral ➝ Buy$280.00High
5/10/2021Piper SandlerBoost TargetOverweight$220.00 ➝ $240.00Medium
5/7/2021Alliance Global PartnersBoost TargetMarket Perform ➝ Buy$230.00 ➝ $240.00Medium
2/25/2021Raymond JamesBoost TargetOutperform$145.00 ➝ $225.00High
2/24/2021Alliance Global PartnersReiterated RatingBuy$167.50 ➝ $230.00High
2/23/2021Piper SandlerBoost TargetOverweight$157.00 ➝ $220.00High
1/29/2021JPMorgan Chase & Co.Initiated CoverageOverweight$195.00High
11/23/2020Piper SandlerBoost TargetOverweight$150.00 ➝ $157.00Medium
11/19/2020Raymond JamesBoost TargetOutperform$140.00 ➝ $145.00High
11/4/2020Alliance Global PartnersBoost TargetBuy$116.50 ➝ $163.50High
10/21/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$125.00High
8/5/2020Alliance Global PartnersBoost TargetBuy$90.00 ➝ $116.50Medium
8/5/2020Piper SandlerUpgradeNeutral ➝ Overweight$87.00 ➝ $110.00High
5/25/2020Piper SandlerLower Target$107.00 ➝ $87.00Medium
5/8/2020Alliance Global PartnersBoost Target$78.00 ➝ $90.00High
4/3/2020Alliance Global PartnersLower TargetAverage ➝ Buy$137.00 ➝ $78.00Low
3/27/2020SidotiLower TargetNeutral$77.00 ➝ $59.00High
1/22/2020Piper SandlerBoost TargetNeutral$86.00 ➝ $107.00Low
1/15/2020SidotiBoost TargetNeutral$72.00 ➝ $77.00High
11/7/2019Raymond JamesDowngradeOutperform ➝ Market PerformMedium
9/18/2019Piper Sandler CompaniesInitiated CoverageNeutral$68.00Low
5/23/2019GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Heska logo
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.
Read More

Today's Range

Now: $119.99
Low: $119.99
High: $119.99

50 Day Range

MA: $119.09
Low: $115.55
High: $119.99

52 Week Range

Now: $119.99
Low: $57.83
High: $120.03

Volume

N/A

Average Volume

241,932 shs

Market Capitalization

$1.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Heska?

The following Wall Street sell-side analysts have issued reports on Heska in the last twelve months: StockNews.com.
View the latest analyst ratings for HSKA.

What is the current price target for Heska?

0 Wall Street analysts have set twelve-month price targets for Heska in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Heska in the next year.
View the latest price targets for HSKA.

What is the current consensus analyst rating for Heska?

Heska currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HSKA.

What other companies compete with Heska?

How do I contact Heska's investor relations team?

Heska's physical mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company's listed phone number is (970) 493-7272 and its investor relations email address is [email protected]. The official website for Heska is www.heska.com. Learn More about contacing Heska investor relations.